Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.
This article summarized the latest R&D progress of Nitrofurazone, the Mechanism of Action for Nitrofurazone, and the drug target R&D trends for Nitrofurazone.
This article summarized the latest R&D progress of Iloperidone, the Mechanism of Action for Iloperidone, and the drug target R&D trends for Iloperidone.
This article summarized the latest R&D progress of Idarucizumab, the Mechanism of Action for Idarucizumab, and the drug target R&D trends for Idarucizumab.
Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.